Physician profile
Kimberley A Gardner
NPI 1275905820
$2,494.49
in general payments reported to CMS, 2019-2025
10 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $45.05 · 2023: $391 · 2024: $672 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,259 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.48 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $808.56 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $537.46 | 2023-2025 | Auvelity |
| Abbvie INC. | $372.20 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $298.73 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $232.33 | 2022-2025 | Spravato |
| Lundbeck LLC | $138.44 | 2024-2025 | Rexulti |
| Alkermes, INC. | $41.66 | 2024 | Aristada, Vivitrol, Lybalvi |
| Ferring Pharmaceuticals INC. | $25.16 | 2024 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $20.71 | 2025 | Trintellix |
| Tris Pharma INC | $19.24 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberley Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.